Efficacy and Safety of Carvedilol on the Treatment of Chronic Congestive Heart Failure

Objectives:To explore the efficacy and safety of treating chronic congestive heart failure(CHF) with carvedilol.Methods:A total of 180 patients with chronic CHF were randomly divided into study group and control group,90 in each.Carvedilol was gradually added to conventional therapy from initial dose to the target or maximum dose tolerated in the study group,while placebo was given in the same pattern as carvedilol in the control group.The course was 24 weeks.The heart rate,blood pressure,echocardiography were measured and heart function was classified with the New York Heart Association(NYHA) classification before and after treatment,as well as adverse effects were recorded.Results:Total efficacy of the study and control groups were 96.67% and 82.22%,respectively.After the treatment,the patients' heart rate and systolic blood pressure were decreased,exercise tolerance index was increased,left ventricular ejection fraction was improved,left ventricular diastolic dimension and left ventricular systolic dimension were decreased,and the expression of noradrenalin,plasma renin activity and angiotensin Ⅱ were decreased in the study group,as compared with the control group with a significant difference(P0.05),and no obvious adverse reactions occurred.Conclusion:Carvedilol based on conventional therapy may be effective to patients with chronic CHF of NYHA grades Ⅱ or Ⅲ,with fewer adverse reactions.